Poster: MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia

Srdan Verstovsek,Ruben Mesa,John Mascarenhas,Tsewang Tashi,Weichung Shih,Toshiaki Sato,Raymond Urbanski,Oleh Zagrijtschuk,Craig Zimmerman

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览1

暂无评分

摘要

The primary endpoint is a durable response defined as the proportion of subjects who achieve simultaneous peripheral blood count remission (platelets ≤400×10/L and WBC <10 × 10/L) for at least 80% of bi-weekly measurements consecutively between weeks 32-52. This study is being sponsored by PharmaEssentia USA.

查看译文

关键词

MPN,myeloproliferative neoplasm,essential thrombocythemia,ropeginterferon alfa-2b-njft,interferon,P1101,Trial-in-Progress

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要